International Cancer Patient Coalition

Uganda



Colorectal Cancer Factsheet: Insights & Key Developments

Key Insights on Colorectal Cancer Care and Infrastructure

Core Pillars:

1. Infrastructure
2. Treatment Access, Research Funding and Awareness Campaigns
3. Survival Rates, Early Detection and Palliative Care
4. Utilization of Biomarkers
5. Clinical Guidelines
6. Reimbursement
7. Colorectal Cancer Screening

Colorectal cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping colorectal cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- Incidence share: Colorectal cancer is rare but increasing.
- Incidence rate: Around 2–3 per 100,000 men per year.
- Total new cases (2022): Approximately 300 men.
- Daily diagnoses (2022): Around 1 man per day.
- Deaths (2022): Around 250 men.
- 5-year survival rate: Likely under 25%, due to late-stage diagnosis and limited treatment access.
- Most affected age group: Men aged 60 and above.
- Screening participation: No organized screening; most cases diagnosed at advanced stages.

International Cancer Patient Coalition

Uganda

Infrastructure



Strengths

- National Cancer Institute (UCI) in Kampala provides specialized cancer care, including CRC treatment.
- Ongoing investments in building regional cancer centers in Gulu, Mbarara, and Mbale

Weakness

- Infrastructure limited mostly to urban centers; rural hospitals lack diagnostic and oncology services.
- Delays in referrals due to poor health system coordination and logistics.

S W O T

Opportunity

- Expansion of telemedicine and mobile health to increase access to cancer care in rural regions.
- International partnerships (e.g., with Fred Hutch, NCI-USA) are bringing investment and training.

Threats

- Frequent power outages and equipment downtime affect continuity of care.
- Overburdened hospitals delay patient throughput and quality of care.

5. Advanced nationwide infrastructure, widespread availability in public and private sectors, integration with clinical practice.

4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.

3. Moderate infrastructure, primarily in private settings or research institutions.

2. Limited infrastructure, available only in select centers or for high-cost private testing.

1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa	3	3
Kenya	2	2
Nigeria	2	2
Egypt	2	3
Morocco	2	2
Algeria	2	2
Ethiopia	1	1
India	3	4
Japan	4	4
South Korea	4	4
China	4	4
Thailand	3	3
Singapore	4	4
United Kingdom	4	4
Germany	5	4
France	4	4
Netherlands	5	4
Sweden	5	4
Italy	4	3
Spain	4	3
Poland	4	3
Mexico	2	3
Brazil	3	3
Argentina	3	3
Chile	3	3
Colombia	2	3
United States	5	5
Canada	5	4
Australia	4	4
New Zealand	4	4
Greece	4	3
Rwanda	1	1
Uganda	1	1
Serbia	3	3
Saudi Arabia	4	4
UAE	4	3
Syria	1	1
Indonesia	2	2
Vietnam	3	3
Philippines	2	2
Russia	3	3
Malaysia	3	3

International Cancer Patient Coalition

Uganda

Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Government and donor-supported chemotherapy programs at UCI allow access to basic treatment.
- Local NGOs like Uganda Cancer Society conduct awareness programs.

Weakness

- Limited access to targeted therapies and radiotherapy; high out-of-pocket costs for many patients.
- Low funding for CRC-specific research compared to cervical or breast cancer.

Opportunity

- Integration of cancer into Universal Health Coverage plans and national essential drug lists.
- Build partnerships with academic institutions to increase CRC research capacity.

Threats

- Funding dependence on international donors makes cancer programs vulnerable to budget cuts.
- Lack of sustained CRC-specific awareness leads to late presentations.

5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.

4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.

3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.

2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.

1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	3	3	3
Kenya	1	1	1
Nigeria	1	1	1
Egypt	2	2	2
Morocco	2	2	2
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	4	4	5
South Korea	4	4	5
China	3	3	3
Thailand	2	3	2
Singapore	4	5	5
United Kingdom	4	5	5
Germany	5	5	5
France	4	4	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	4	4	4
Spain	4	4	4
Poland	3	3	3
Mexico	2	3	3
Brazil	2	3	3
Argentina	2	3	3
Chile	2	3	3
Colombia	1	2	2
United States	5	5	5
Canada	5	5	5
Australia	4	4	4
New Zealand	3	3	3
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	2	3	3
Saudi Arabia	3	2	3
UAE	4	3	4
Syria	1	1	1
Indonesia	2	2	2
Vietnam	2	1	2
Philippines	3	2	2
Russia	3	3	2
Malaysia	3	3	3

International Cancer Patient Coalition

Uganda

Survival Rates, Early Detection and Palliative Care



Strengths

- Efforts underway to integrate palliative care into national hospitals and community health.
- Uganda is one of Africa's leaders in morphine distribution for cancer pain management.

Weakness

- Most CRC cases diagnosed at Stage III or IV; 5-year survival rate estimated below 15%.
- Screening and early detection services nearly absent for CRC.

Opportunity

- Scale-up FIT testing and awareness campaigns via community health workers.
- Expand palliative care training for rural clinicians and home-based caregivers.

Threats

- Limited trained oncology staff and pathologists delays diagnosis and staging.
- Cultural beliefs may deter patients from seeking early or palliative care.

S W O T

5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.

4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.

3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.

2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.

1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa	2	3	2
Kenya	1	1	1
Nigeria	1	1	1
Egypt	2	2	2
Morocco	2	2	2
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	5	4	5
South Korea	5	4	5
China	3	3	4
Thailand	2	2	2
Singapore	5	5	5
United Kingdom	5	5	5
Germany	5	5	5
France	5	4	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	5	4	5
Spain	5	4	5
Poland	3	3	4
Mexico	2	2	2
Brazil	3	3	3
Argentina	3	3	3
Chile	3	3	3
Colombia	2	2	2
United States	5	5	5
Canada	5	5	5
Australia	5	4	4
New Zealand	4	4	3
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	2	3	2
Saudi Arabia	3	2	3
UAE	4	3	4
Syria	1	1	1
Indonesia	2	2	2
Vietnam	2	1	2
Philippines	2	3	2
Russia	4	3	3
Malaysia	3	2	3

International Cancer Patient Coalition

Uganda

Utilization of Biomarkers



Strengths

- Pilot programs in Kampala hospitals occasionally utilize KRAS and MSI testing in research settings.
- UCI has started incorporating basic molecular testing for high-priority cases.

Weakness

- Biomarker testing is rare and unaffordable for the general population.
- Lack of local labs means samples are often sent abroad, delaying results.

S W O T

Opportunity

- Set up regional molecular pathology units through partnerships and grants.
- Train pathologists in biomarker interpretation to enable targeted therapies.

Threats

- High costs and lack of reimbursement limit uptake.
- Shortage of reagents, technical expertise, and stable lab infrastructure.

Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.

Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.

Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.



International Cancer Patient Coalition

Uganda

Clinical Guidelines



Strengths

- National Cancer Control Plan includes CRC as a priority cancer for surveillance and treatment.
- UCI clinicians often follow international protocols for CRC staging and therapy.

Weakness

- No Uganda-specific CRC clinical guidelines tailored to local infrastructure and epidemiology.
- Variability in treatment protocols among non-specialized hospitals.

S W O T

Opportunity

- Create simplified, resource-adapted CRC treatment guidelines endorsed by MOH.
- Use electronic health tools to disseminate standardized care pathways.

Threats

- Inconsistent implementation due to staffing and supply issues in district hospitals.
- Delays in guideline updates hinder adoption of latest clinical practices.

	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	✖	✖	✖	✖	O
Feasibility of Integration	✖	✖	✖	✖	O
Adoption of International Guidelines	✖	✖	✖	✖	O
Engagement with Updates	✖	✖	✖	O	✖
ESMO Guidelines Implementation	✖	✖	✖	✖	O

International Cancer Patient Coalition

Uganda

Reimbursement

Strengths

- Some essential chemotherapy drugs provided for free at UCI and supported centers.
- Palliative morphine is subsidized and widely available.

Weakness

- No national insurance program; most patients pay out-of-pocket for imaging, surgery, or private treatment.
- Biomarker tests and advanced therapies not covered under public schemes.

S W O T

Opportunity

- Integrate cancer into Uganda's upcoming National Health Insurance Scheme.
- Introduce subsidies for diagnostics and biosimilars to improve affordability.

Threats

- Economic hardship and inflation limit patient ability to seek and complete treatment.
- Heavy donor dependence may disrupt supply of subsidized drugs.

● A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.

● A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.

● No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement Framework	No-cost Access
United States	●	○
United Kingdom	●	●
Canada	●	●
Australia	●	●
Germany	●	●
France	●	●
Netherlands	●	●
Sweden	●	●
Italy	●	●
Spain	●	●
Poland	●	●
Japan	●	●
South Korea	●	●
China	●	●
India	○	○
Singapore	●	●
Thailand	●	●
South Africa	○	○
Kenya	○	○
Nigeria	○	○
Egypt	○	○
Morocco	○	○
Algeria	●	●
Ethiopia	○	○
Mexico	●	●
Brazil	●	●
Argentina	●	●
Chile	●	●
Colombia	●	●
New Zealand	●	●
Greece	●	●
Rwanda	○	○
Uganda	○	○
Serbia	●	●
Saudi Arabia	●	●
UAE	●	●
Syria	○	○
Indonesia	●	○
Vietnam	●	○
Philippines	○	○
Russia	●	●
Malaysia	●	●

International Cancer Patient Coalition

Uganda

Colorectal Cancer Screening

Strengths

- Pilot screening projects in Kampala have tested the feasibility of FIT and colonoscopy programs.
- CRC has been added to long-term national cancer priorities.

Weakness

- No nationwide CRC screening policy or program exists.
- Awareness of CRC symptoms and screening is very low, especially among men over 40.



Opportunity

- Utilize community health worker networks to roll out education and home-based FIT screening.
- Integrate CRC risk assessment in routine outpatient visits and NCD programs.

Threats

- Inadequate follow-up infrastructure for positive screening results.
- Competing health priorities (e.g., HIV, TB) may limit political focus on CRC.

Country	Colorectal Cancer Screening
United States	Annual LDCT (50-80 years, high-risk smokers)
United Kingdom	LDCT for high-risk individuals (55-74 years)
Canada	LDCT for high-risk individuals (55-74 years)
Australia	No national program, high-risk groups advised LDCT
Germany	No national program, under evaluation
France	No national LDCT screening
Netherlands	Participating in European screening studies
Sweden	No national LDCT screening
Italy	Regional pilot LDCT screening
Spain	No national LDCT program
Poland	No national program
Japan	No national LDCT program
South Korea	LDCT for high-risk individuals (50-74 years)
China	No national LDCT program
India	No national LDCT program
Singapore	No national LDCT program
Saudi Arabia	No national LDCT program; some hospital-based opportunistic screening
UAE	No national LDCT program; early-stage pilot studies ongoing in select hospitals
Syria	No national LDCT program; screening not prioritized due to conflict
Malaysia	No program; high-risk CT pilots

Country	Colorectal Cancer Screening
Thailand	No national LDCT program
South Africa	No national LDCT program
Kenya	No national LDCT program
Nigeria	No national LDCT program
Egypt	No national LDCT program
Morocco	No national LDCT program
Algeria	No national LDCT program
Ethiopia	No national LDCT program
Mexico	No national LDCT program
Brazil	No national LDCT program
Argentina	No national LDCT program
Chile	No national LDCT program
Colombia	No national LDCT program
New Zealand	No national LDCT program
Greece	No national LDCT program
Rwanda	No national LDCT program
Uganda	No national LDCT program
Serbia	No national LDCT program
Indonesia	No national LDCT program; opportunistic screening in private sector
Vietnam	No national LDCT program; early pilot screening studies in Hanoi and Ho Chi Minh
Philippines	No national LDCT program; feasibility and awareness programs under discussion
Russia	No formal national LDCT program; regional pilot screening programs in large cities